Allogene Therapeutics, Inc. - ALLO
About Gravity Analytica
Recent News
- 06.12.2025 - Statement of changes in beneficial ownership of securities
- 06.10.2025 - Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
- 06.04.2025 - Jefferies Global Healthcare Conference
- 06.01.2025 - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- 06.01.2025 - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- 06.01.2025 - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- 06.01.2025 - ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study
- 06.01.2025 - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- 06.01.2025 - ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
- 05.27.2025 - TD Cowen